Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

Author(s):

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations

EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP: 3.Exploring the TROPION-Lung04 Study

EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP: 5.Navigating Between ADCs in NSCLC

EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP: 8.MARIPOSA Study Insights

EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC

EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01

EP: 14.Challenges and Learnings from EVOKE-01

EP: 15.Key ADC Studies at ASCO 2024

Now Viewing

EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP: 17.Patient Selection and Sequencing of NSCLC ADCs

How do the toxicities of Dato-DXd, sacituzumabgovitecan and HER3-DXd compare? How are you managing these in your clinical practice?
- Hayashi et al. ELCC 2024. HER3-DXd in previously treated patients with advanced EGFR mutated NSCLC: Updated safety results from HERTHENA-Lung01
- Sands et al. ASCO 2024. Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).